Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia.

@article{Treon2004PolymorphismsIF,
  title={Polymorphisms in Fc$\gamma$RIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia.},
  author={Steven P P Treon and Mark Hansen and Andrew R. Branagan and Christos E. Emmanouilides and Eva Kimby and Stanley R. Frankel and Nikolaos Touroutoglou and David G. Maloney and Kenneth C. Anderson and Edward A. Fox},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2004},
  volume={22 14\_suppl},
  pages={6556}
}
  • S. TreonM. Hansen E. Fox
  • Published 15 July 2004
  • Medicine, Biology
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
6556 Background: Polymorphisms in FcγRIIIA (CD16) receptor expression modulate human IgG1 binding, and antibody dependent cell mediated cytotoxicity, and may therefore impact responses to rituximab in patients with WM. METHODS We therefore performed sequencing of all DNA coding regions for FcγRIIIA in 58 patients with Waldenstrom's macroglobulinemia (WM) treated with rituximab. Two distinct, but linked polymorphisms (FcγRIIIA-48 and -158) were commonly observed. All patients with FcγRIIIA… 

Figures and Tables from this paper

Genetic Linkage of FcgγRIIa and FcγRIIIa and Implications for Their Use in Predicting Clinical Responses to CD20-Directed Monoclonal Antibody Therapy

The results of these studies demonstrate that there is wide linkage within and between polymorphisms in FcγRIIa and F cγRIIIa and might provide an explanation for why polymorphisms at Fc εIIa are associated with rituximab responses despite a lack of impact on IgG1 binding.

The impact of FcγRIIa and FcγRIIIa gene polymorphisms on responses to RCHOP chemotherapy in diffuse large B-cell lymphoma patients

The findings of the present study indicate that FcγR polymorphisms have no influence on the survival of DLBCL patients.

The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab.

The interaction of R-CHOP, but not CHOP with FcγRIIIa polymorphisms, indicates a window of opportunity for CD20 antibodies designed to mediate enhanced antibody-dependent cellular cytotoxicity.

The loss of the CD16 B73.1/Leu11c epitope occurring in some primary immunodeficiency diseases is not associated with the FcgammaRIIIa-48L/R/H polymorphism.

It is suggested that the loss of the B73.1/Leu11c binding epitope is connected with primary immunodeficiency disorders, but not associated with the FcgammaRIIIa-48 polymorphism.

FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.

The FCGR3A single nucleotide polymorphism (SNP) is predictive of response to R-CHOP, but does not correlate with survival in patients with DLBCL, and FcR polymorphism can affect rituximab's affinity for ADCC effector cells.

FCGR2C genotyping by pyrosequencing reveals linkage disequilibrium with FCGR3A V158F and FCGR2A H131R polymorphisms in a Caucasian population

A strong and a weaker linkage disequilibrium associating the FCGR2C-ORF allele with the FC GR3A-158V and the FC2A-131H allele, respectively are demonstrated.

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism.

Results suggest that individuals expressing at least one valine at FcgammaRIIIa-158 might, in part, have better clinical outcomes due to increased CD16 expression, rituximab binding, and ritUXimab-mediated, antibody-dependent cellular cytotoxicity (ADCC).

The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study

The 158VV FCGR3A genotype was associated with response to RTX in a large cohort of RA patients and may be helpful to plan RTX treatment, and May be integrated with clinical predictors.

Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma.

The high affinity FcgammaRIIIa 158 V allele is associated with rituximab-induced neutropenia after autologous transplantation and is a potential tool to identify a high-risk population for developing neutropania after antibody therapy.
...

References

SHOWING 1-10 OF 30 REFERENCES

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene.

This study showed an association between the FCGR3A genotype and clinical and molecular responses to rituximab, and will certainly give rise to new pharmacogenetic approaches to the management of patients with non-Hodgkin lymphomas.

FcγRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype

Differences in IgG binding among the three Fc gammaRIIIa-48L/R/H isoforms are a consequence of the linked, biallelic Fc Gamma receptor IIIa-158V/F polymorphism at amino-acid position 158.

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

The data suggest that FcRIIIa polymorphisms are not predictive of response in CLL and that, unlike the case with FL, mechanisms of tumor clearance other than antibody-dependent cellular cytotoxicity may be more important.

CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom’s Macroglobulinemia

It is demonstrated that rituximab is an active agent in Waldenstrom's macroglobulinemia, a B-cell lymphoproliferative disorder in which CD20 is expressed on tumor cells from most patients.

CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia.

  • S. TreonD. Agus J. Byrd
  • Medicine, Biology
    Journal of immunotherapy : official journal of the Society for Biological Therapy
  • 2001
It is demonstrated that rituximab is an active agent in Waldenstrom's macroglobulinemia, a B-cell lymphoproliferative disorder in which CD20 is expressed on tumor cells from most patients.

Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype.

Differences in IgG binding among the three Fc gammaRIIIa-48L/R/H isoforms are a consequence of the linked, biallelic Fc Gamma receptor IIIa-158V/F polymorphism at amino-acid position 158.

A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease.

Initial analysis of 200 patients with SLE indicates a strong association of the low binding phenotype with disease, especially in patients with nephritis who have an underrepresentation of the homozygous high binding phenotype.

Two Immunoglobul in G Fragment C Receptor Polymorphisms Independent ly Predic t Response to Rituximab in Pat ients With Fol l icular Lymphoma

Data support the hypothesis that ADCC plays an important role in the clinical effect of rituximab at the level of the effector cell and are found to be independently associated with the response rate and freedom from progression.

Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations.

Combined mAb therapy might be a useful approach to cope with variation in lymphoplasmacytic lymphoma, and could be tailored to target all members of the tumor clone for an individual patient.

Extended rituximab therapy in Waldenström's macroglobulinemia.

Data show that extended rituximab therapy is active and may lead to more major responses over standard dose ritUXimab in Waldenström's macroglobulinemia, and WM patients with serum IgM levels of <6000 mg/dl are more likely to benefit from extended ritsumab therapy.